Revolutionizing Medicine through Pharmacogenomics

Phone: (919) 465-0100 | pharmadx@cgix.com

Date: March 21 – 27, 2015
Location: Boston, MA

Date: March 3-7, 2015
Location: New Orleans, LA

> CGI’s genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC)
> Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year

RUTHERFORD, NJ, February 24, 2015 (Globe Newswire) – Cancer Genetics Inc (Nasdaq: CGIX; “CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, announced today that it has identified genomic signatures that can differentiate those patients with clear cell renal carcinoma (ccRCC) whose disease is likely to relapse or metastasize.  The signatures were identified in a collaborative study with Memorial Sloan-Kettering Cancer Center (MSKCC) which analyzed and genomically assessed specimens from 144 patients with both primary and metastatic lesions. Genomic signatures identified in this study have the potential to allow for better risk stratification and guided treatment selection for patients with metastatic ccRCC. CGI plans on integrating signatures identified in this study into an NGS-based panel for kidney cancer, which the company expects to be CLIA-certified and available for use for both clinical trials and clinical diagnosis and management of patients.

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, with approximately 43,000 new cases diagnosed in the US each year. Approximately 20-30% of ccRCC patients relapse within three years after nephrectomy. Identifying patients whose disease is likely to relapse or metastasize is essential for planning appropriate treatment strategies and improving outcome. Copy number variations in samples from patients whose disease had metastasized to the lung or bone (the two most common sites for metastasis of ccRCC) were also identified and validated in an independent dataset. For patients with early-stage disease, accurate prediction of metastatic activity will enable the delivery of personalized precision medicine with the goal of improving outcomes.

Results of the study will be presented at the Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU-ASCO). The poster presentation, titled “Association of genome-wide copy number alterations with metastasis of clear cell renal cell carcinoma” will be delivered by Banumathy Gowrishankar, Ph.D., principal clinical scientist at Cancer Genetics, on February 28 at 7:00am Eastern Time at the Rosen Shingle Creek in Orlando, Florida.

About the Genitourinary Cancers Symposium

The Genitourinary Cancers Symposium is a specialized oncology event designed for the exchange of the latest strategies in prevention, screening, diagnosis, and treatment of prostate, renal, testicular, and urothelial cancers. The symposium is cosponsored by the American Society for Clinical Oncology (ASCO), American Society for Therapeutic and Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO).

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic, Columbia University and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Contacts:

Media Relations
Alison Burchett
Cancer Genetics, Inc.
201-528-2053
media@cgix.com

Investor Relations
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568

  • CGI’s unique next generation sequencing (NGS) panel, Focus::CLLTM, will be used to assess genetic aberrations and mutations that are clinically relevant and validated for CLL, the most common form of leukemia in the Western hemisphere.
  • CLL accounts for one-third of all leukemias and the Focus::CLLTM panel helps in determining patient outcome and treatment selection.

RUTHERFORD, N.J. and RESEARCH TRIANGLE, N.C., Feb. 17, 2015 (GLOBE NEWSWIRE) — Cancer Genetics, Inc.(Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that its unique genomic panel for CLL, Focus::CLLTM, has been selected to provide genomic information for CLL patients in a global clinical trial. The trial is expected to assess several hundred patient specimens during 2015. Focus::CLLTM will be used to help guide patient stratification and management during the trial. The NGS-based panel is the only clinically validated, disease-focused genomic panel being offered in a commercial clinical setting for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Focus::CLLTM is approved for clinical use by the Clinical Laboratory Improvement Amendments (CLIA).

The Focus::CLLTM panel assesses genes with clinical relevance for prognosis, disease management, and treatment selection. The targeted NGS panel was designed to offer actionable and immediately relevant information for clinicians. With an analytical sensitivity of 5%, the test is able to detect biomarker mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. Improved sensitivity can lead to enhanced diagnostic and prognostic capabilities for this disease and improved patient outcomes. In addition to being available as an individual test, Focus::CLLTMhas been integrated into the company’s CompleteTM offering for CLL/SLL.

“Our highly focused and custom NGS panel for CLL affords excellent depth of detection of variants in genes of high prognostic value in CLL patients,” said Jane Houldsworth, Ph.D., Vice President of Research and Development at CGI. “For the first time, comprehensive, robust mutation analysis down to at least 5% sensitivity of genes such as TP53, NOTCH1, SF3B1, and uniquely ATM and BIRC3 are being offered in a clinically-regulated setting with results made available to clinicians in a streamlined and informative report to assist in the management of CLL patients.”

CGI’s Focus::CLLTM allows for rapid and highly sensitive sequencing of clinically validated genomic aberrations associated with CLL. The global clinical trial builds upon CGI’s focus on hematological malignancies, and its goal of helping to empower the personalized treatment and management of cancer patients.

“CGI is developing a series of focused, clinically actionable NGS panels that will help deliver actionable information to help patients and clinicians both in routine treatment and in clinical trials,” said Panna Sharma, CEO and President of CGI. “We have seen the need by both payers and biopharma companies to have more targeted, clinically actionable information delivered to influence and guide personalization in an era of targeted, pathway specific therapeutics. Our strategy is to continue developing unique, disease-focused NGS panels that can accelerate the adoption of biomarker driven personalization for cancer patients, aid clinicians and cancer centers, and power clinical trials.”

Chronic lymphocytic leukemia accounts for roughly one-third of all newly diagnosed cases of leukemia, with about 15,700 cases diagnosed in the US each year. Due to disease’s clinical heterogeneity, risk stratification and prognostication is especially important for patient selection in CLL trials.

The company also offers its proprietary MatBA® tests for diffuse large B-cell lymphoma (DLBCL), CLL, follicular lymphoma (FL), and mantle cell lymphoma (MCL) as part of its comprehensive testing for blood-borne cancers.

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic, Columbia University and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Contacts:
Media Relations

Alison Burchett
Cancer Genetics, Inc.
201-528-2053
media@cgix.com

Investor Relations
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568

 

Date: February 15 – 20, 2015
Location: San Francisco, CA

RUTHERFORD, N.J., Feb. 12, 2015 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that CEO and President Panna Sharma will participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th.

The conference, which is held at the Cliff Lodge in Snowbird, Utah, brings together more than 50 leading growth companies from the healthcare industry and 100 institutional investors from major mutual and hedge funds.

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic, Columbia University and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Contacts:

Media Relations
Alison Burchett
Cancer Genetics, Inc.
201-528-2053
media@cgix.com

Investor Relations
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568

 

RUTHERFORD, NJ, February 11, 2015 (Globe Newswire) – Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management. Goodman is a nationally recognized expert in value-based reimbursement and brings more than 20 years of experience from both the public and private sector in the field of health economics and healthcare policy to CGI. Goodman will be responsible for reimbursement, managed care, payer access and revenue cycle management.

“The importance of optimizing revenue cycle management has become crucial in an environment where changing policies dictate reimbursement rate and influence laboratory practices,” said Panna Sharma, CEO of Cancer Genetics. “Randy’s experience will be an asset for CGI in working with major payors, and in improving access for patients and payers to CGI’s best-in-class precision diagnostics.”

Goodman has vast experience in reimbursement strategy, and has directed pricing, international reimbursement, and market strategies for a variety of global and U.S. healthcare and device companies. Prior to joining CGI, Goodman served as project director for health economics, reimbursement strategy, and health care policy at Precision for Medicine.  From 2009 to 2011, Goodman served as senior director of global health economics and reimbursement strategy at ImpediMed, Inc. While there, he was responsible for the development and implementation of the organization’s global health economic and reimbursement policies.  Prior to his time at ImpediMed, Goodman was the director of health economics, policy, and reimbursement for Access MediQuip, LLC, where he developed a new platform for acquiring and managing surgical and implantable devices.

Goodman also brings tremendous expertise in public healthcare economics and policy. Goodman served as a health care reform policy consultant to the White House Office on Health Reform, and was a policy consultant to Presidents Clinton and Obama. He has developed recommendations adopted in Medicare, Medicaid, managed-care payer, and long-term health care reforms, and brings a comprehensive understanding of new payment methodologies mandated by the Affordable Care Act of 2010.

“I am very excited to be part of a growth organization dedicated to advancing personalized medicine and cancer treatment,” said Goodman. “This specific role offers me the opportunity to help improve patient outcomes, reduce the cost of cancer treatment, and help CGI grow into a global molecular diagnostics organization. As payment and health economic models continue to evolve, there exists an opportunity for CGI to play an important leadership role in how we deliver and account for personalized cancer diagnostics in the years to come.”

Goodman holds a master’s degree in healthcare administration from Harvard University and received his Ph.D. in Healthcare Administration and Policy from Harvard University’s School of Public Health.

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

 Contact:

Media Relations
Alison Burchett
Cancer Genetics, Inc.
201-528-2053
Alison.burchett@cgix.com

Investor Relations
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

RUTHERFORD, N.J., January 20, 2014 (GlobeNewswire) – Cancer Genetics, Inc., (Nasdaq: CGIX) (“CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, announced today the launch of their ExpandDxTM collaborative testing program. CGI’s ExpandDx program, which utilizes VENTANA digital pathology technology from Roche, allows community-based hospitals and pathology labs to partner with CGI through remote consultations, and enables access to a broader range of tests that expand the clinical testing capabilities of community labs and hospitals. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases.

“We are very excited to partner with Cancer Genetics to provide comprehensive digital pathology solutions through their ExpandDx testing program,” said Rod Cotton, Senior Vice President at Roche Diagnostics Corporation.  “This new service is an example of their innovation and leadership in the field of cancer diagnostics. It will enable a more collaborative and responsive diagnosis process for community-based pathologists and help them fulfill their mission to empower personalized cancer treatment.”

Through CGI’s ExpandDx collaborative testing program, the technical component will be performed at CGI laboratories, and clinicians will have the option of interpreting and signing out their patients’ test results. By allowing clinicians to sign out cases remotely and share cases with other team members, the program enables smaller labs to manage resources while still leveraging CGI’s unique tests and expertise in oncology diagnostics.

“As care centers and clinicians look for ways to improve cost efficiency, technical-only testing offers opportunity for providers to more actively collaborate in the diagnosis process and manage costs for patients,” said Lan Wang, M.D., Medical Director at Cancer Genetics.  “CGI’s ExpandDx technical-only testing will ensure that community-based hospitals and pathology labs have access to the same cutting-edge oncology testing available at larger centers, and will allow the clinical community to collaborate on difficult cases.”

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT:
Media Relations
Alison Burchett
Cancer Genetics, Inc.
201-528-2053
alison.burchett@cgix.com

Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997

Source: Cancer Genetics, Inc.

>> Approval Allows CGI to Access Largest National Market for Oncology Testing Services

RUTHERFORD, N.J., January 05, 2015 (Globe Newswire) –Cancer Genetics, Inc. (Nasdaq: CGIX, “CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, announced today that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.

“Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth. CGI is well positioned to continue to empower the personalization of treatment by providing our unique technologies and tests for a region that demands innovation and access to world-class medical technology,” said Panna Sharma, CEO of Cancer Genetics. “Although cancer rates in the State of California are relatively stable, there is a tremendous need to improve the costs associated with patient management and therapeutic selection, and provide molecular insights that can enable earlier and more comprehensive diagnosis. We will work closely with our partners, and with our sales and commercial team, to add value for clinicians, cancer centers, and regional providers to enable better, more informed diagnosis and prognosis of cancer.”

In 2014, more than 171,000 new cases of cancer were diagnosed in the State of California, representing more than 10 percent of the total cancer incidence in the United States.  The company believes that its proprietary tests and complete programs for Non-Hodgkin’s Lymphoma (NHL) and leukemia will be of particular benefit to California, where more than 6,800 new patients are diagnosed with NHL, and 4,300 additional patients are diagnosed with leukemia each year.

About Cancer Genetics

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT:

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com

Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997

Source: Cancer Genetics, Inc.

RUTHERFORD, N.J., and HYDERABAD, INDIA, December 16, 2014 (GLOBE NEWSWIRE) – Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors.

“Mr Bobba has a tremendous track record of leadership in the life sciences. His experiences and insights will bring significant value to CG India’s board of directors,” said Panna Sharma, CEO and President of Cancer Genetics, Inc.

Bobba brings with him more than 36 years of corporate leadership experience in the pharmaceutical and life sciences industries.  Bobba, who is currently a General Partner with Ventureast, has held executive leadership positions at a number of life sciences companies in the US, EU, and Asia.  Prior to joining Ventureast, Bobba served as Senior Vice President of Operations at Aradigm Corporation and from 2001-2003 was Executive Vice President at Diosynth, a division of Akzo Nobel.  From 1995 to 2000, Bobba served as President and CEO at Molecular Biosystems, an NYSE listed company. Previous to that, Bobba was Executive Vice President of Centocor Inc (now Jansen Biotech, a division of Johnson & Johnson) and held several executive positions, including President, at Warner-Lambert, Indonesia. He also previously served as V.P. of Manufacturing at Parke-Davis, USA (now part of Pfizer).

“It is an exciting time to be part of such a high-growth market like India. I look forward to the growth and much needed innovation that CG India will bring to Indian cancer patients and hospitals at an affordable price,” said Bobba. “CG India has established itself as a leader in the oncology diagnostics market with a firm commitment to innovation. I look forward to helping the company offer novel cancer diagnostic tests to all patients who need them to improve their clinical outcomes.”

Bobba is an active board member of three US-based companies, including Diabetomics Inc., Melior Pharma, and Sparsha Inc. Bobba also sits on the board of several Indian-based companies, including Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he serves on the advisory board for the SOHO Group, the largest pharmaceutical company in Indonesia, and for Cumberland Pharmaceuticals, Inc., USA, a Nasdaq listed company.

A pharmacist by training, Bobba graduated with gold medal honors from Andhra University and holds an MBA from Farleigh Dickinson University, New Jersey.

About Cancer Genetics

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT:

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com

Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997


Our Services

At Gentris, we believe in providing the highest level of quality services to meet our customer’s needs. From our CAP Accredited biorepository, to our CLIA regulated laboratory, we strive to be the leader in pharmacogenomics solutions.